The American Journal of Managed Care6d
CROI to Present New Insights on Long COVID Risk, HIV Cure
One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...
The American Journal of Managed Care3d
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
Medscape3h
Ensitrelvir Shows Promise for COVID-19 Prevention Following Exposure
The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close contact with someone who is infected vulnerable to developing COVID ...
Study examines a novel way to bring addiction care and HIV prevention to people who inject drugs
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
BioWorld1d
Long COVID science is progressing, though therapies have not yet followed
In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary ...
aidsmap10d
aidsmap returns with reporting from the Conference on Retroviruses and Opportunistic Infections (CROI)
News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...
El Mundo on MSN2d
New advance against HIV: a single annual injection against the infection
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
Healio1h
Long-acting treatment benefits postpartum women with HIV and their babies
Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...
Managed Healthcare Executive21h
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Gilead Presents New HIV Treatment And Cure Research Data
Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...